Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nov 09 2012 Cyclacel Pharmaceuticals to Announce Release of Third Quarter 2012 Financial Results Nov 07 2012 Cyclacel to Present at Lazard Healthcare Conference Nov 06 2012 Personalized Medicine Potential of Cyclacel's Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer Conference Nov 05 2012 Cyclacel Receives $1.9 Million Translational Medicine Grant Award From the UK Biomedical Catalyst to Advance Its CYC065 Targeted Drug for Leukemias Nov 01 2012 Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology Oct 15 2012 Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure Oct 12 2012 Updated Phase 2 Survival Data of Cyclacel's Sapacitabine for MDS Presented at The Eighth Annual Hematologic Malignancies 2012 Conference Oct 02 2012 Cyclacel to Present at BIO Investor Forum Sep 13 2012 Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement Aug 29 2012 Cyclacel to Present at Stifel Nicolaus 2012 Healthcare Conference Aug 24 2012 Cyclacel Announces Reverse Stock Split Aug 14 2012 Cyclacel Reports Second Quarter 2012 Financial Results Aug 10 2012 Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2012 Financial Results Jun 04 2012 Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting Jun 01 2012 Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting May 17 2012 Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting May 14 2012 Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2/3 Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine May 14 2012 Cyclacel Reports First Quarter 2012 Financial Results May 08 2012 Cyclacel Pharmaceuticals to Announce Release of First Quarter 2012 Financial Results Apr 17 2012 Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine Apr 04 2012 Personalized Medicine and Combination Potential of Cyclacel's Sapacitabine Highlighted at AACR Apr 02 2012 Cyclacel's Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at AACR Mar 29 2012 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results Mar 26 2012 Cyclacel to Announce Year-End and Fourth Quarter 2011 Financial Results and Multiple Presentations at the Upcoming AACR Conference Mar 22 2012 Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses on Certain Intellectual Property Pagination First page « first Previous page ‹ previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nov 09 2012 Cyclacel Pharmaceuticals to Announce Release of Third Quarter 2012 Financial Results Nov 07 2012 Cyclacel to Present at Lazard Healthcare Conference Nov 06 2012 Personalized Medicine Potential of Cyclacel's Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer Conference Nov 05 2012 Cyclacel Receives $1.9 Million Translational Medicine Grant Award From the UK Biomedical Catalyst to Advance Its CYC065 Targeted Drug for Leukemias Nov 01 2012 Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology Oct 15 2012 Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure Oct 12 2012 Updated Phase 2 Survival Data of Cyclacel's Sapacitabine for MDS Presented at The Eighth Annual Hematologic Malignancies 2012 Conference Oct 02 2012 Cyclacel to Present at BIO Investor Forum Sep 13 2012 Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement Aug 29 2012 Cyclacel to Present at Stifel Nicolaus 2012 Healthcare Conference Aug 24 2012 Cyclacel Announces Reverse Stock Split Aug 14 2012 Cyclacel Reports Second Quarter 2012 Financial Results Aug 10 2012 Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2012 Financial Results Jun 04 2012 Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting Jun 01 2012 Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting May 17 2012 Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting May 14 2012 Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2/3 Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine May 14 2012 Cyclacel Reports First Quarter 2012 Financial Results May 08 2012 Cyclacel Pharmaceuticals to Announce Release of First Quarter 2012 Financial Results Apr 17 2012 Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine Apr 04 2012 Personalized Medicine and Combination Potential of Cyclacel's Sapacitabine Highlighted at AACR Apr 02 2012 Cyclacel's Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at AACR Mar 29 2012 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results Mar 26 2012 Cyclacel to Announce Year-End and Fourth Quarter 2011 Financial Results and Multiple Presentations at the Upcoming AACR Conference Mar 22 2012 Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses on Certain Intellectual Property Pagination First page « first Previous page ‹ previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page next › Last page last »
Nov 06 2012 Personalized Medicine Potential of Cyclacel's Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer Conference
Nov 05 2012 Cyclacel Receives $1.9 Million Translational Medicine Grant Award From the UK Biomedical Catalyst to Advance Its CYC065 Targeted Drug for Leukemias
Nov 01 2012 Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
Oct 15 2012 Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure
Oct 12 2012 Updated Phase 2 Survival Data of Cyclacel's Sapacitabine for MDS Presented at The Eighth Annual Hematologic Malignancies 2012 Conference
Jun 04 2012 Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting
May 17 2012 Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting
May 14 2012 Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2/3 Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine
Apr 04 2012 Personalized Medicine and Combination Potential of Cyclacel's Sapacitabine Highlighted at AACR
Mar 26 2012 Cyclacel to Announce Year-End and Fourth Quarter 2011 Financial Results and Multiple Presentations at the Upcoming AACR Conference
Mar 22 2012 Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses on Certain Intellectual Property
